Recent progress of targeted nanocarriers in diagnostic, therapeutic, and theranostic applications in colorectal cancer

• Published in: Biomaterials advances 2023-10, Vol.153, p.213556-213556, Article 213556
• Main Authors: Choudhury, Hira, Pandey, Manisha, Saravanan, Vilashini, Mun, Amanda Tan Yee, Bhattamisra, Subrat Kumar, Parikh, Ankit, Garg, Sanjay, Gorain, Bapi
• Format: Article
• Language: English
• ISSN: 2772-9508; 2772-9508
• DOI: 10.1016/j.bioadv.2023.213556

Cancer at the lower end of the digestive tract, colorectal cancer (CRC), starts with asymptomatic polyps, which can be diagnosed as cancer at a later stage. It is the fourth leading cause of malignancy-associated mortality worldwide. Despite progress in conventional treatment strategies, the possibility to overcome the mortality and morbidity issues with the enhancement of the lifespan of CRC patients is limited. With the advent of nanocarrier-based drug delivery systems, a promising revolution has been made in diagnosis, treatment, and theranostic purposes for cancer management. Herein, we reviewed the progress of miniaturized nanocarriers, such as liposomes, niosomes, solid lipid nanoparticles, micelles, and polymeric nanoparticles, employed in passive and active targeting and their role in theranostic applications in CRC. With this novel scope, the diagnosis and treatment of CRC have proceeded to the forefront of innovation, where specific characteristics of the nanocarriers, such as processability, flexibility in developing precise architecture, improved circulation, site-specific delivery, and rapid response, facilitate the management of cancer patients. Furthermore, surface-engineered technologies for the nanocarriers could involve receptor-mediated deliveries towards the overexpressed receptors on the CRC microenvironment. Moreover, the potential of clinical translation of these targeted miniaturized formulations as well as the possible limitations and barriers that could impact this translation into clinical practice were highlighted. The advancement of these newest developments in clinical research and progress into the commercialization stage gives hope for a better tomorrow.